AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04129944
Drug: UBX0101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug intra-articular injection
Trial: NCT02714296
Drug: Nutridrink 200 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
Trial: NCT02519543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be given twice daily, once with breakfast and once with supper
Trial: NCT03023189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
Trial: NCT03843125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04480307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
Trial: NCT00570128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation matched to active treatment for oral administration.
Trial: NCT02224053
Drug: AZD9291 tablet dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
Trial: NCT00050076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
Trial: NCT00376740
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
Trial: NCT00842816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets to match ST101 tablets
Trial: NCT02911935
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
Trial: NCT02911935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension
Trial: NCT00172016
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00001217
Drug: pre-surgical chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01745081
Drug: Hypertonic saline 3% bolus administration
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02608476
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Trial: NCT02522780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Granules in sachet; Route of administration: Oral use
Trial: NCT04066257
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline hydrochloride 250 mg capsule
Trial: NCT02260635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00669435
Drug: Losartan + Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months
Trial: NCT00669435
Drug: Amlodipine + Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months
Trial: NCT01745887
Drug: EBI-005-2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
Trial: NCT02729207
Drug: Esflurbiprofen Hydrogel Patch
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One patch per day for 7 days
Trial: NCT02365909
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
Trial: NCT01358253
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
Trial: NCT01358253
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
Trial: NCT01358253
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
Trial: NCT02117505
Drug: Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
Trial: NCT04145245
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
Trial: NCT00959569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normosaline (same ml of the study drug)
Trial: NCT02973581
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
Trial: NCT00918307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
Trial: NCT02311517
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02227550
Drug: Vitamin K antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
Trial: NCT01266603
Drug: HDIL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
Trial: NCT03901690
Drug: Betaglucin soluble gel 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
Trial: NCT03079427
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
Trial: NCT00959439
Drug: Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00959439
Drug: Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01801917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet for oral administration
Trial: NCT01737944
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vibex MTX Device
Trial: NCT04615312
Drug: a CDK4 / 6 inhibitor and a MEK inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
Trial: NCT01845064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01747577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02735694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
Trial: NCT05188924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00603512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00603512
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00603512
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00603512
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00603512
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT04330495
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
Trial: NCT02266940
Drug: DS-1971a suspension
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
Trial: NCT02266940
Drug: DS-1971a tablet
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 200 mg DS 1971a tablet for oral administration
Trial: NCT01833169
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
Trial: NCT00105157
Drug: Comparator: MK0518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0518 oral tablets 200 mg b.i.d, for 24 weeks
Trial: NCT00105157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to MK0518, oral tablet b.i.d, for 24 weeks
Trial: NCT04011098
Drug: Epidural Fentanyl Bolus
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
Trial: NCT04011098
Drug: Standard Epidural Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
Trial: NCT03037424
Drug: Cryoprecipitate
RxNorm normalized name: Cryoprecipitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
Trial: NCT02889302
Drug: KPS-0373
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks
Trial: NCT02889302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks
Trial: NCT02966340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00658593
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01550380
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
Trial: NCT02977689
Drug: IDH305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
Trial: NCT00707707
Drug: AZD2281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose finding study to establish the appropriate dose of AZD2281
Trial: NCT01104948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259348
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV)
Trial: NCT00929981
Drug: Tablet Methylprednisolone (4 or 16 mg)
RxNorm normalized name: methylprednisolone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
Trial: NCT02520453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01585428
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
Trial: NCT00131482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
Trial: NCT00806962
Drug: Adjuvant/Excipients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
Trial: NCT02502968
Drug: Placebo (for BL-8040)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for solution for injection manufactured to mimic BL-8040
Trial: NCT01056926
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
Trial: NCT03535103
Drug: Gonal-F®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single Subcutaneous injection, 225IU
Trial: NCT00815945
Drug: PegLiposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
Trial: NCT00608231
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
Trial: NCT02564042
Drug: GSK2894512 1% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Trial: NCT02564042
Drug: GSK2894512 0.5% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Trial: NCT02564042
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to off-white vehicle cream base to be applied topically
Trial: NCT00396955
Drug: PLA-695
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006034
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04556734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod matching placebo tablet by mouth, once daily
Trial: NCT01349790
Drug: NewGam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
Trial: NCT04058145
Drug: AMD3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
Trial: NCT02937506
Drug: Fentanyl Plus Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
Trial: NCT03589443
Drug: Multiplexed heptapeptides
RxNorm normalized name: hexapeptide-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptapeptides QRH and KSP
Trial: NCT03686163
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
Trial: NCT01142700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 0 mg, once daily
Trial: NCT01069796
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
Trial: NCT00779467
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl 2 mcg/ml
Trial: NCT00617123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo oral tablet
Trial: NCT02289898
Drug: Abraxane®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT02289898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04622124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02846883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of Plasmalyte A (placebo)
Trial: NCT00676650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg/day, oral, administered on a continuous daily dosing regimen
Trial: NCT04262739
Drug: NYH817G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
Trial: NCT02697617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01257581
Drug: creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: creatine monohydrate powder
Trial: NCT00381849
Drug: Cystone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.
Trial: NCT05544656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo administered three times a day
Trial: NCT02937207
Drug: Ke Chuan Liu Wei Mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experience formula of famous traditional Chinese professor Yingen Wu
Trial: NCT02937207
Drug: Chuan Xiong Ping Chuan Mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experience formula of famous traditional Chinese professor Changrong Shao
Trial: NCT02937207
Drug: Zhi Chuan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experience formula of famous traditional Chinese professor Yingen Wu
Trial: NCT02937207
Drug: Ke Chuan Liu Wei Mixture placebo
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
Trial: NCT02937207
Drug: Chuan Xiong Ping Chuan Mixture placebo
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
Trial: NCT02937207
Drug: Xie Wu Capsule placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose combination for treating prescription of Xie Wu Capsule
Trial: NCT02937207
Drug: Dan Ma Jia Tablet placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose combination for treating prescription of Dan Ma Jia Tablet
Trial: NCT01765270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg placebo tablet daily
Trial: NCT01628549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched Placebo capsule administered as an oral capsule(s) once daily